In a 12-1 vote Dec. 15, the agency’s Cardiovascular and Renal Drugs Advisory Committee ruled that new evidence supports use of the heart failure drug sacubitril/valsartan to treat patients in heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback